{
    "root": "271e876d-55ae-4f6b-bf83-532298722dd9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Alprazolam"
    },
    "value": "20250528",
    "ingredients": [
        {
            "name": "ALPRAZOLAM",
            "code": "YU55MQ3IZY"
        },
        {
            "name": "SILICA",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE 2208 (4000 MPA.S)",
            "code": "39J80LT57T"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": "alprazolam extended-release tablets indicated treatment panic disorder without agoraphobia , adults .",
    "contraindications": "recommended starting oral 0.5 mg 1 mg daily ( preferably morning ) . depending response , dose may increased intervals 3 4 days increments 1 mg daily . ( 2.1 ) recommended total daily 3 mg 6 mg daily . ( 2.1 ) swallow tablets whole ; divide , crush , chew . ( 2.1 ) tapering , decrease 0.5 mg every 3 days . patients may require even slower reduction . ( 2.2 , 5.2 ) full prescribing information recommended geriatric patients , patients hepatic impairment , ritonavir . ( 2.3 , 2.4 , 2.5 )",
    "warningsAndPrecautions": "product : 50090-7556 ndc : 50090-7556-1 60 tablet , extended release bottle",
    "adverseReactions": "alprazolam extended-release tablets contraindicated patients : known hypersensitivity alprazolam benzodiazepines . angioedema reported [ ( 6.2 ) ] . taking strong cytochrome p450 3a ( cyp3a ) inhibitors ( e.g . , ketoconazole , itraconazole ) , except ritonavir [ ( 2.5 ) , ( 5.5 ) , ( 7.1 ) ] .",
    "indications_original": "Alprazolam extended-release tablets are indicated for the treatment of panic disorder with or without agoraphobia, in adults.",
    "contraindications_original": "Recommended starting oral dosage is 0.5 mg to 1 mg once daily (preferably in the morning). Depending on the response, the dose may be increased at intervals of 3 to 4 days in increments of no more than 1 mg daily. ( 2.1 ) Recommended total daily dosage is 3 mg to 6 mg daily. ( 2.1 ) Swallow tablets whole; do not divide, crush, or chew. ( 2.1 ) When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. ( 2.2 , 5.2 ) See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir. ( 2.3 , 2.4 , 2.5 )",
    "warningsAndPrecautions_original": "Product:    50090-7556\n                  NDC:    50090-7556-1   60 TABLET, EXTENDED RELEASE in a BOTTLE",
    "adverseReactions_original": "Alprazolam extended-release tablets are contraindicated in patients:\n                  \n                  \n                     with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported [see Adverse Reactions (6.2)].\n                     taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir [see Dosage and Administration (2.5), Warnings and Precautions (5.5), Drug Interactions (7.1)]."
}